Literature DB >> 1506812

A prospective study of the incidence of deep-vein thrombosis within a defined urban population.

M Nordström1, B Lindblad, D Bergqvist, T Kjellström.   

Abstract

In a prospective study all positive phlebographies within the well-defined population of the city of Malmö, Sweden, during 1987 were studied in order to determine the incidence of deep venous thrombosis (DVT). Epidemiological data were analysed for the detection of patient groups at increased risk of DVT. The incidence was found to be equal for both sexes, i.e. 1.6 per 1000 inhabitants a year. Risk factors were found to be in accordance with earlier studies. The median age for men was 66 years, compared to 72 years for women. At diagnosis of DVT, 19% of subjects had a known malignancy and within 1 year 5% (19 cases) developed a new malignancy. Of the men, 29% had postoperative or post-traumatic (fracture) DVT, compared to 46% of the women. Fewer patients with DVT than expected (39%) belonged to blood group 0 (31%) (P less than 0.005). Pulmonary embolism (PE) was clinically suspected in only 5% of cases, and diagnosis was verified scintigraphically in 2% of cases. None of these died of PE, but of 6 patients who were found to have PE at autopsy, four died about 4 weeks after the DVT was diagnosed.

Entities:  

Mesh:

Year:  1992        PMID: 1506812     DOI: 10.1111/j.1365-2796.1992.tb00565.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  89 in total

Review 1.  Suspected deep vein thrombosis: a management algorithm for the accident and emergency department.

Authors:  S Nawaz; P Chan; S Ireland
Journal:  J Accid Emerg Med       Date:  1999-11

Review 2.  Cardiovascular health and aromatase inhibitors.

Authors:  Kathleen I Pritchard; Beth L Abramson
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Usefulness of factor V Leiden mutation testing in clinical practice.

Authors:  Ellen Ø Blinkenberg; Ann-Helen Kristoffersen; Sverre Sandberg; Vidar M Steen; Gunnar Houge
Journal:  Eur J Hum Genet       Date:  2010-03-24       Impact factor: 4.246

Review 4.  Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism.

Authors:  D K Cundiff; J Manyemba; J C Pezzullo
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 5.  The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

Authors:  Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

6.  The cost-benefit ratio of screening pregnant women for thrombophilia.

Authors:  Gian Luca Salvagno; Giuseppe Lippi; Massimo Franchini; Giovanni Targher; Martina Montagnana; Massimo Franchi; Gian Cesare Guidi
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

7.  Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Authors:  Linda C Johansson; Lars Frison; Ulrika Logren; Gunnar Fager; David Gustafsson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study.

Authors:  Anja B U Mäkelburg; Nic J G M Veeger; Saskia Middeldorp; Karly Hamulyák; Martin H Prins; Harry R Büller; Willem M Lijfering
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

9.  No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.

Authors:  Troy C Sarich; Renli Teng; Gary R Peters; Maria Wollbratt; Robert Homolka; Mia Svensson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.

Authors:  Gunnar Fager; Marie Cullberg; Maria Eriksson-Lepkowska; Lars Frison; Ulf G Eriksson
Journal:  Eur J Clin Pharmacol       Date:  2003-07-04       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.